Pherecydes Pharma Société anonyme

ENXTPA:ALPHE Stock Report

Market Cap: €14.4m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Pherecydes Pharma Société anonyme Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Thibaut Fayet

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenureno data
Board average tenure1.1yrs

Recent management updates

Recent updates

CEO

Thibaut Fayet (55 yo)

less than a year

Tenure

Mr. Thibaut du Fayet served as Chief Operating Officer and served as Member of the Executive Board at Pherecydes Pharma Société anonyme since April 2022 until May 19, 2022 and served as its Deputy Chief Ex...

Board Members

NamePositionTenureCompensationOwnership
Franck Lescure
Director1.1yrsno datano data
Eric Leire
Director1.1yrsno datano data
Didier Hoch
Independent Chairman1.1yrsno datano data
Maryvonne Hiance
Independent Vice Chairwoman of the Boardno datano datano data
Leila Nicolas
Director1.1yrsno datano data
Guy Rigaud
Director1.1yrsno data0.018%
€ 2.6k
Robert Sebbag
Director1.1yrsno datano data
Saima Aslam
Member of Medical Advisory Boardless than a yearno datano data
Marc Bonten
Member of Medical Advisory Boardless than a yearno datano data
Tristan Ferry
Member of Medical Advisory Boardless than a yearno datano data
Yok-Ai Que
Member of Medical Advisory Boardless than a yearno datano data
Martin Witzenrath
Member of Medical Advisory Boardless than a yearno datano data

1.1yrs

Average Tenure

66yo

Average Age

Experienced Board: ALPHE's board of directors are not considered experienced ( 1.1 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/06/26 04:58
End of Day Share Price 2023/06/26 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pherecydes Pharma Société anonyme is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Arnaud DesprePortzamparc BNP Paribas
Mohamed KaabouniPortzamparc BNP Paribas
Claire DerayTPICAP Midcap